TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16322398

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp30) administered via multiple daily injections for 12 weeks
Number of subjects: 23
Study: 11910301

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 84

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 84
Study: 9637640

Group type: EXPERIMENTAL
Intervention: Lateral approach to popliteal block (PB) with 40 ml 1.5% alkalinized mepivacaine with 1:200,000 epinephrine.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Posterior approach to popliteal block (PB) with 40 ml 1.5% alkalinized mepivacaine with 1:200,000 epinephrine.
Number of subjects: 50
Study: 8202904

Group type: EXPERIMENTAL
Intervention: Respiratory questionnaire and spirometric tests
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Spirometric tests
Number of subjects: 409

Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 409
Study: 2973269

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide inhaled as a dry powder (40 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ipratropium bromide by pressurized aerosol (two puffs of 20 micrograms; total 40 micrograms)
Number of subjects: 15
Study: 31771424

Group type: EXPERIMENTAL
Intervention: Senhance robotic system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic technique
Number of subjects: 40
Study: 29871809

Group type: EXPERIMENTAL
Intervention: MOM hip prostheses
Number of subjects: 95
Study: 28244205

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan eligibility criteria applied to patients on target doses of ACE inhibitors or ARBs
Number of subjects: 6131

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan eligibility criteria applied to all patients regardless of background medication
Number of subjects: 6131

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan eligibility criteria applied to patients with HFrEF
Number of subjects: 6131

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan eligibility criteria applied ignoring background medication
Number of subjects: 6131
Study: 25819691

Group type: EXPERIMENTAL
Intervention: Oral eliglustat
Number of subjects: 160

Group type: COMPARATOR
Intervention: Imiglucerase
Number of subjects: 160
Study: 23894336

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone and aripiprazole)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (race-matched subjects without schizophrenia)
Number of subjects: 69
Study: 21199699

Group type: EXPERIMENTAL
Intervention: 2009 A/H1N1 MF59‐adjuvanted influenza vaccine administered simultaneously with seasonal virosomal‐adjuvanted influenza vaccine
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2009 A/H1N1 MF59‐adjuvanted influenza vaccine administered sequentially with seasonal virosomal‐adjuvanted influenza vaccine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Seasonal vaccine administered alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of pandemic and seasonal vaccines
Number of subjects: 72
Study: 18653228

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 410
Study: 17175653

Group type: EXPERIMENTAL
Intervention: Intervention to change health behaviour
Number of subjects: 0
Study: 14680667

Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Feeling Thermometer (FT)
Number of subjects: 84
Study: 11600556

Group type: EXPERIMENTAL
Intervention: Nateglinide (60 mg) premeal (‐10,‐1 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nateglinide (60 mg) postmeal (+10 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nateglinide (60 mg) before meals (10 min before)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nateglinide (60 mg) after meals (10 min after)
Number of subjects: 12
Study: 9732163

Group type: EXPERIMENTAL
Intervention: 0.5% PFPE-containing o/w emulsion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0% PFPE-containing o/w emulsion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.0% PFPE-containing o/w emulsion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4.0% PFPE-containing o/w emulsion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Emulsion base alone
Number of subjects: 10
Study: 7981071

Group type: EXPERIMENTAL
Intervention: OND/MPD (8 mg OND i.v. injection and 120 mg MPD i.v. injection before chemotherapy, followed by 8 mg OND tablet and 16 mg MPD tablet orally for 3-5 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: OND (8 mg OND plus placebo i.v. injection before chemotherapy, followed by 8 mg OND tablet and placebo orally for 3-5 days)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: OND/MPD
Number of subjects: 102
Study: 2663321

Group type: EXPERIMENTAL
Intervention: miglitol (BAY‐m‐1099)
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 30610502

Group type: EXPERIMENTAL
Intervention: Combined chitosan and Dan-shen injection
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Chitosan
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Dan-shen
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (recanalization alone)
Number of subjects: 400
Study: 27435886

Group type: EXPERIMENTAL
Intervention: 25% glucose
Number of subjects: 94

Group type: COMPARATOR
Intervention: 24% sucrose
Number of subjects: 94
Study: 26199693

Group type: EXPERIMENTAL
Intervention: Light Cycler SeptiFast (LC-SF) test
Number of subjects: 86

Group type: COMPARATOR
Intervention: Blood culture (BC)
Number of subjects: 86
Study: 23275433

Group type: EXPERIMENTAL
Intervention: Wearing eye goggles and earmuffs for a 4‐hour period in the NICU
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control period (no eye goggles and earmuffs)
Number of subjects: 54
Study: 21802081

Group type: EXPERIMENTAL
Intervention: MedDiet with supplemental virgin olive oil (VOO)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: MedDiet with supplemental nuts
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 187
Study: 19365152

Group type: EXPERIMENTAL
Intervention: Cataract patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Glaucoma patients
Number of subjects: 69

Group type: COMPARATOR
Intervention: Overall correlation
Number of subjects: 69
Study: 16919531

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/d, 12 weeks)
Number of subjects: 20
Study: 15023777

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 488
Study: 11371410

Group type: EXPERIMENTAL
Intervention: Heat-killed Mycobacterium vaccae (0.5 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Delipidated deglycolipidated Mycobacterium vaccae (DDMV) (0.05 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (placebo)
Number of subjects: 43
Study: 9418711

Group type: EXPERIMENTAL
Intervention: Heparinized normal saline
Number of subjects: 35

Group type: COMPARATOR
Intervention: Heparinized culture medium
Number of subjects: 35
Study: 8105829

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31364105

Group type: EXPERIMENTAL
Intervention: Vaginal Soft gels technology
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 85
Study: 28850362

Group type: EXPERIMENTAL
Intervention: Oxycodone 15mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 50
Study: 26083699

Group type: EXPERIMENTAL
Intervention: 12-week guided skiing program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG) instructed not to change daily routines and not allowed to ski
Number of subjects: 26
Study: 23280514

Group type: EXPERIMENTAL
Intervention: MJ-dependent group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-MJ-dependent group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study: 21585703

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 18326964

Group type: EXPERIMENTAL
Intervention: Low-dose diuretic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple medications
Number of subjects: 0
Study: 17042849

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study: 12747879

Group type: EXPERIMENTAL
Intervention: ICL670 at 10 mg x kg(‐1) x day(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ICL670 at 20 mg x kg(‐1) x day(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ICL670 at 40 mg x kg(‐1) x day(‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10815250

Group type: EXPERIMENTAL
Intervention: Mixture of C. sempervirens and C. japonica extracts
Number of subjects: 0
Study: 8623996

Group type: EXPERIMENTAL
Intervention: Desflurane (increased at 1% per min)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Desflurane (increased at 0.5% per min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isoflurane (increased at 0.16% per min)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Desflurane (both groups)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 23
Study: 1455882

Group type: EXPERIMENTAL
Intervention: Hyperthermic conditions (39.5 degrees C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normothermic conditions (37 degrees C)
Number of subjects: 10
Study: 6397330

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide plus 50 mg triamterene
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride
Number of subjects: 20
Study: 30738698

Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 46
Study: 28590992

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26051494

Group type: EXPERIMENTAL
Intervention: Inositol-enriched beverage (IEB) containing 2.23 g of inositols in 250 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sucrose-sweetened beverage (SB)
Number of subjects: 40
Study: 25456755

Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin
Number of subjects: 70

Group type: COMPARATOR
Intervention: 5 mg/day atorvastatin
Number of subjects: 70
Study: 22345434

Group type: EXPERIMENTAL
Intervention: Rowing ergometry and biweekly strength training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rowing ergometry and biweekly strength training with volume loading
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sedentary bed rest
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exercise alone (Rowing ergometry and strength training)
Number of subjects: 27
Study: 20830491

Group type: EXPERIMENTAL
Intervention: Midazolam group (50 μg/kg midazolam added to 3 mg/kg lidocaine 2% w/v)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (3 mg/kg lidocaine 2% w/v diluted with saline to 40 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam group
Number of subjects: 40
Study: 17580330

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15912389

Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors
Number of subjects: 5462
Study: 12479119

Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Oral testosterone
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Viagra
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Psychological treatment + Viagra
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Intraurethral PGE1
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Intracavernous injection
Number of subjects: 227
Study: 9656089

Group type: EXPERIMENTAL
Intervention: Computer-administered rating scales (LSAS, BSPS, Fear Questionnaire)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-administered rating scales
Number of subjects: 0
Study: 7584286

Group type: EXPERIMENTAL
Intervention: High imagery text
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low imagery text
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imageability manipulated within-subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Listening to high imagery text
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Listening to low imagery text
Number of subjects: 0
Study: 2744903

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1089401

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0
Study: 30829962

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET), n = 14
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual Care (UC), n = 14
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exercise Qc
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Stroke Volume (SV) during exercise
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Resting left ventricular ejection fraction
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Troponin levels
Number of subjects: 28
Study: 27654852

Group type: EXPERIMENTAL
Intervention: PR1 peptide vaccine (0.25, 0.5 or 1.0 mg, administered subcutaneously every 3 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PR1 peptide vaccine
Number of subjects: 66
Study: 25764483

Group type: EXPERIMENTAL
Intervention: Low-level laser (LLL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Desensitizing paste (DP) containing 8% arginine-calcium carbonate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Laser followed by desensitizing paste (LLL+DP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Desensitizing paste followed by laser (DP+LLL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study: 23661722

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in inoperable cohort
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in paradoxical low-flow cohort
Number of subjects: 971

Group type: COMPARATOR
Intervention: Medical management in inoperable cohort
Number of subjects: 971

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement
Number of subjects: 971
Study: 21084649

Group type: EXPERIMENTAL
Intervention: Exercise before protein intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest before protein intake
Number of subjects: 0
Study: 20128231

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with monomeric allergoid at a dosage of 1000 AU five times a week for two years
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (drug therapy)
Number of subjects: 40
Study: 16924050

Group type: EXPERIMENTAL
Intervention: Parent-based intervention materials encouraging communication about skin cancer risks and promoting sun-safe behaviors.
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (no intervention materials provided).
Number of subjects: 340
Study: 12761456

Group type: EXPERIMENTAL
Intervention: Colonic pacing in study group (11 patients)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Colonic pacing in healthy volunteers
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (8 patients, no pacing)
Number of subjects: 19
Study: 11061104

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 55
Study: 8956810

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 81
Study: 1388220

Group type: EXPERIMENTAL
Intervention: Continuous combined oestradiol valerate/cyproterone acetate (2 mg E2V + 1 mg CPA daily)
Number of subjects: 49
Study: 3895386

Group type: EXPERIMENTAL
Intervention: Psychotherapy combined with medical treatment for IBS
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Psychotherapy combined with medical treatment for PUD
Number of subjects: 204

Group type: COMPARATOR
Intervention: Medical treatment only for IBS
Number of subjects: 204

Group type: COMPARATOR
Intervention: Medical treatment only for PUD
Number of subjects: 204
Study: 31135633

Group type: EXPERIMENTAL
Intervention: Retroflexed Viewing (RV) using the RetroView colonoscope
Number of subjects: 225

Group type: COMPARATOR
Intervention: Forward Viewing (FV)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Forward Viewing (FV) and Retroflexed Viewing (RV)
Number of subjects: 225
Study: 28870196

Group type: EXPERIMENTAL
Intervention: Email elicitation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Face-to-face elicitation
Number of subjects: 15
Study: 25659440

Group type: COMPARATOR
Intervention: Tranexamic acid (TXA) administration: bolus dose of 15 mg/kg 10 min before tourniquet inflation, intra-articular administration of 3 grams 10 min before tourniquet deflation, IV infusion of 10 mg/kg/h for 3 h after completion on the second side.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tranexamic acid (TXA) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25058218

Group type: EXPERIMENTAL
Intervention: Everolimus, 7.5 mg/d
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study: 22334768

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 200/10 μg
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 400 μg
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Formoterol (F) 10 μg
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1055
Study: 19243713

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d for 8 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d for 8 weeks (subgroup of clinically responsive patients)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls (untreated)
Number of subjects: 18
Study: 17435976

Group type: EXPERIMENTAL
Intervention: Continuation of ACEI therapy (premed group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Withdrawal of ACEI therapy (withdrawal group)
Number of subjects: 100
Study: 15385353

Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT (group M; n = 109)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard propofol LCT with 20 mg lidocaine (group L; n = 113)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard propofol LCT with 20 mg lidocaine (group L)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT (group M)
Number of subjects: 222
Study: 11238801

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) at doses between 2.4 and 7.2 g/d
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) at 7.2 g/d
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) at all levels of supplementation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9792483

Group type: EXPERIMENTAL
Intervention: Emotionally loaded film stimuli (amusement and disgust)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reaction time (RT) task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold pressor (CP) task
Number of subjects: 0
Study: 7639417

Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (1200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 2502040

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) 20 mg p.o. (five doses during 30 hr preceding ethanol intake)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ethanol 1 g/kg p.o. during 1 hr
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 943420

Group type: EXPERIMENTAL
Intervention: 0.1 ppm NO2 exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unpolluted air exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.2 ppm NO2 exposure
Number of subjects: 20
Study: 31953832

Group type: EXPERIMENTAL
Intervention: Stent attached to Foley catheter and removed together
Number of subjects: 163

Group type: COMPARATOR
Intervention: Cystoscopy for stent removal
Number of subjects: 163
Study: 31535460

Group type: EXPERIMENTAL
Intervention: l-arginine (ARG: 3.2 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: wheat protein hydrolysate (WPH: 2 g) + l-arginine (ARG: 3.2 g)
Number of subjects: 27
Study: 28002542

Group type: EXPERIMENTAL
Intervention: Training with 24 different talkers
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Passage-based transcription training
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sentence-based single-talker training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (transcribing unvocoded sentence materials)
Number of subjects: 64
Study: 26030264

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 96
Study: 23848096

Group type: EXPERIMENTAL
Intervention: Lamb consumption (Ternasco de Aragón)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chicken-based diet
Number of subjects: 50
Study: 22013950

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1150